Evidence map›Paper›PMID 33230178›Full record

ArticleScientific reports2020

Central nervous system pathology in preclinical MPS IIIB dogs reveals progressive changes in clinically relevant brain regions.

Martin T Egeland, Marta M Tarczyluk-Wells, Melissa M Asmar, Evan G Adintori, Roger Lawrence, Elizabeth M Snella, Jackie K Jens, Brett E Crawford, Jill C M Wait, Emma McCullagh and 3 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.7field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 2 countries.

Martin T EgelandThe Lundquist Institute at Harbor-UCLA Medical Center, and David Geffen School of Medicine, UCLA, Torrance, CA, USA.
Marta M Tarczyluk-WellsKing's College London, Institute of Psychiatry, Psychology and Neuroscience, Maurice Wohl Clinical Neuroscience Institute, London, UK.
Melissa M AsmarKing's College London, Institute of Psychiatry, Psychology and Neuroscience, Maurice Wohl Clinical Neuroscience Institute, London, UK.
Evan G AdintoriBioMarin Pharmaceutical Inc., Novato, CA, USA.
Roger LawrenceBioMarin Pharmaceutical Inc., Novato, CA, USA.
Elizabeth M SnellaIowa State University, Ames, IA, USA.
Jackie K JensIowa State University, Ames, IA, USA.
Brett E CrawfordBioMarin Pharmaceutical Inc., Novato, CA, USA.
Jill C M WaitBioMarin Pharmaceutical Inc., Novato, CA, USA.
Emma McCullaghBioMarin Pharmaceutical Inc., Novato, CA, USA.
Jason PinkstaffBioMarin Pharmaceutical Inc., Novato, CA, USA.
Jonathan D CooperThe Lundquist Institute at Harbor-UCLA Medical Center, and David Geffen School of Medicine, UCLA, Torrance, CA, USA. cooperjd@wustl.edu.
N Matthew EllinwoodIowa State University, Ames, IA, USA.
BioMarin (United States) · USIowa State University · USKing's College London · GBHarbor–UCLA Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mucopolysaccharidosis type IIIB (MPS IIIB; Sanfilippo syndrome B) is an autosomal recessive lysosomal storage disorder caused by the deficiency of alpha-N-acetylglucosaminidase activity, leading to increased levels of nondegraded heparan sulfate (HS). A mouse model has been useful to evaluate novel treatments for MPS IIIB, but has limitations. In this study, we evaluated the naturally occurring canine model of MPS IIIB for the onset and progression of biochemical and neuropathological changes during the preclinical stages (onset approximately 24-30 months of age) of canine MPS IIIB disease. Even by 1 month of age, MPS IIIB dogs had elevated HS levels in brain and cerebrospinal fluid. Analysis of histopathology of several disease-relevant regions of the forebrain demonstrated progressive lysosomal storage and microglial activation despite a lack of cerebrocortical atrophy in the oldest animals studied. More pronounced histopathology changes were detected in the cerebellum, where progressive lysosomal storage, astrocytosis and microglial activation were observed. Microglial activation was particularly prominent in cerebellar white matter and within the deep cerebellar nuclei, where neuron loss also occurred. The findings in this study will form the basis of future assessments of therapeutic efficacy in this large animal disease model.

Indexed as

AcetylglucosaminidaseAnimalsAstrocytesCerebellumCerebral CortexDisease Models, AnimalDisease ProgressionDog DiseasesDogsFemaleHeparan SulfateHistocytochemistryHumansLysosomesMaleMicrogliaAcetylglucosaminidaseHeparan Sulfate

Identifiers

PMID33230178
PMCPMC7684310
OpenAlexW3109330739

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.